Analysts Initiate Positive Ratings on Two Healthcare Stocks: Valeant Pharmaceuticals Intl Inc (VRX), TG Therapeutics Inc (TGTX)
Stifel and FBR Capital analysts came out today with new ratings and price targets on a handful of healthcare stocks. Lets take a look and see what they have to say about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and TGTherapeutics Inc (NASDAQ:TGTX).
Valeant Pharmaceuticals Intl Inc
After joining Stifel healthcare equity research team in July, analyst Adam Walsh initiated coverage on shares of Valeant Pharma, with a Buy rating and price target of $160, which represents a potential upside of 62% from where the stock is currently trading.
In explaining his positive Buy rating Walsh stated, “With Orkambi ramping, Kalydeco still growing, and a host of new pipeline medicines steadily marching toward/through the clinic, Vertex remains well positioned to sustain and expand its dominant leadership position in cystic fibrosis (CF), in our view. In addition, we think the omnipresent prospect of a Vertex take-out puts a floor under shares near current levels.”
“Near term, the Orkambi launch will likely remain in focus, and our recent checks with multiple CF key opinion leader (KOL) physicians and the lead medical director of a major U.S. payer suggest uptake remains steady, and the payer environment is relatively benign,” the analyst added.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Adam Walsh has a total average return of 22% and a 54% success rate. Walsh is ranked #374 out of 3644 analysts.
Out of the 21 analysts polled by TipRanks in the last 3 months, 14 rate Valeant Pharmaceuticals stock a Buy, 6 rate the stock a Hold and 1 recommends a Sell. With a return potential of 61.02%, the stock’s consensus target price stands at $159.06.